Related Experiment Video
Updated: Apr 25, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
8.3K
What are the pharmacotherapy options for treating prediabetes?
Giuseppe Daniele1, Muhammad Abdul-Ghani, Ralph A DeFronzo
1University of Texas Health Science Center at San Antonio, Division of Diabetes , 7703 Floyd Curve Dr, San Antonio, TX, 78229 , USA +1 210 567 6691 ; +1 210 567 6554 ; albarado@uthscsa.edu.
Expert Opinion on Pharmacotherapy
|August 21, 2014
Summary
Pharmacotherapy, including thiazolidinediones (TZDs) and glucagon-like peptide-1 (GLP-1) analogs, effectively prevents type 2 diabetes mellitus (T2DM) progression in prediabetes. Metformin is less effective, while weight loss is challenging to maintain long-term.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) incidence is epidemic, incurring significant costs.
- Prediabetes, characterized by impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG), precedes T2DM.
- Prediabetes involves insulin resistance and beta-cell dysfunction, offering intervention opportunities.
Purpose of the Study:
- To review pharmacologic agents for preventing T2DM progression from prediabetes.
- To evaluate interventions that improve insulin sensitivity and preserve beta-cell function.
Main Methods:
- Review of pharmacologic agents studied for T2DM prevention.
- Analysis of agents' efficacy in delaying IGT to T2DM conversion.
Main Results:
- Weight loss improves insulin sensitivity and beta-cell function, reducing T2DM progression, but long-term adherence is difficult.
- Thiazolidinediones (TZDs) are highly effective in T2DM prevention.
- Long-acting glucagon-like peptide-1 (GLP-1) analogs effectively prevent IGT progression to T2DM by augmenting beta-cell function and promoting weight loss.
- Metformin demonstrates considerably lower efficacy compared to TZDs or GLP-1 analogs.
Conclusions:
- Pharmacotherapy offers a viable alternative to lifestyle interventions for T2DM prevention in prediabetes.
- TZDs and GLP-1 analogs are effective pharmacologic strategies for managing prediabetes and preventing T2DM.
- While weight loss is beneficial, pharmacologic interventions provide a more consistently effective approach for T2DM prevention.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
987
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
987
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
947
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
947
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K